Sharing surveillance data: the value of collaboration in curbing the next pandemic

Routine drug resistance surveillance is essential for monitoring and controlling the spread of diseases and has proven to be a critical element of addressing the COVID-19 pandemic. Routine surveillance is also a crucial element in controlling the rise of antimicrobial resistance.

Date

20 November 2020

Download the full publication

In this viewpoint, authors Francesca Chiara (Senior Advisor, Drug Resistant Infections Programme, Wellcome); Moska Hellamand (Researcher, Access to Medicine Foundation); and Margo Warren (Government Engagement and Policy Manager, Access to Medicine Foundation) make the case for pharmaceutical companies to share surveillance data sets publicly, including and through the AMR Register.

This viewpoint covers:

The current landscape of drug surveillance
How drug surveillance is currently gathered and used in both the public and private sectors
How data from pharmaceutical companies is valuable in furthering understanding of drug resistance
How combining surveillance data can improve research and development outcomes
How the Access to Medicine Foundation and Wellcome's Drug Resistant Infections Team are working together to promote transparency and the wider use of industry data